You may have been told before that low molecular weight heparin is more effective than oral anticoagulant therapy for patients with cancer associated DVTs or pulmonary emboli – after all, that data is now over 10 years old. After that though, there are still many more questions to be answered.
How long do you keep going for? How do you manage recurrence? How do you handle those who have a high risk of bleeding? What role do the new anticoagulants play?
There’s a nice little review in Blood that covers these questions and more. Have a read over here.
source | blood
image | Pulmonary Pathology